The Clinical Core will provide expertise in the development, implementation and coordination of the clinical translational research trials performed in the Breast Cancer SPORE. The ultimate goal is to develop improved therapies for patients with or at risk of developing breast cancer through a better understanding of the biology of these cancers. To achieve this goal, the major responsibilities of the Clinical Core will be to 1) provide expertise in the development and implementation of translational clinical trials related to the SPORE projects;2) assure and maintain adequate accrual of patients that participate in SPORE-initiated clinical trials;3) provide research nurse, regulatory, data manager and specimen procurement support for these clinical trials;4) monitor and assure the safety of research subjects, adherence to institutional and federal regulatory requirements, and compliance with protocol-specified activities;and 5) oversee the timely and accurate entry of data into the OnCore and Breast SPORE databases. During the previous grant period, the Clinical Core provided support for 4 therapeutic clinical trials that accrued 140 patients overall. The Core's efforts were pivotal in coordinating data collection and transfer from collaborating institutions participating in some of these trials. In the competing renewal, the Clinical Core will support 6 clinical trials within Projects 1, 2 and 3. Project 1 clinical trials include a neoadjuvant study with combined ER and HER2 blockade in patients with ER+/HER2+ operable breast cancers and a pre-surgical study with endocrine blockade in ER+ operable breast cancers;Project 2 clinical trials include a phase I study with paclitaxel/ cisplatin/ RAD001 in metastatic breast cancer patients and a phase II neo-adjuvant study with paclitaxel/cisplatin +/- RAD001 in stage II and III patients with triple-negative breast cancers;and Project 3 clinical trials include a phase I and phase II studies with bisphosphonates, endocrine therapy and TGFbeta antibodies in patients with ER+ metastatic breast cancer and bone metastasis. These studies are the clinical/ translationai complement to the specific aims associated with each of these Project in the Breast Cancer SPORE. Knowledge and insights gained from these trials will be used to design follow-up trials to be conducted in larger, confirmatory trials as inter-SPORE or cooperative group collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA098131-08
Application #
8182327
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
8
Fiscal Year
2010
Total Cost
$166,092
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Santos Guasch, Gabriela L; Beeler, J Scott; Marshall, Clayton B et al. (2018) p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. iScience 8:236-249
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Elion, David L; Cook, Rebecca S (2018) Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget 9:29007-29017
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Luo, Na; Nixon, Mellissa J; Gonzalez-Ericsson, Paula I et al. (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9:248
Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel et al. (2018) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clin Cancer Res :
Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858
Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191
Edwards, Deanna N; Ngwa, Verra M; Wang, Shan et al. (2017) The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ. Sci Signal 10:

Showing the most recent 10 out of 341 publications